|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
BioPharm Insight
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Eurand in Licenses Corticosteroid GI Product From Chiesi Farmaceutici SpA
4/15/2008
PHILADELPHIA, April 15, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that Chiesi Farmaceutici SpA, an Italian pharmaceutical company, has granted Eurand Pharmaceuticals Inc. (Eurand), Affiliate of Eurand N.V., an exclusive license to its gastro-resistant, controlled release tablet formulation of the corticosteroid, beclomethasone dipropionate, in the United States and Canada. The product is currently approved and marketed in the United Kingdom, Italy, Spain, and Belgium.
|
|
|
|
|
|
|
|
|
|
|
|